Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular safety of insulin degludec versus insulin glargine in high-risk type 2 diabetes
2013-002371-17Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Time to first major adverse cardiovascular event (MACE). Started Oct 2013; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-002371-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002371-17.